TACSTD2 and breast cancer: As a key finding of this study, we reported here that co-treatment of breast cancer cells with decitabine that increased TROP2 expression substantially enhanced cell sensitivity to SG, and the combination of these two agents led to a profound synergistic antitumor efficacy.